(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ENAVISE

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

ENAVISE

ST13

US500000079329526

Class

5

Filing

79329526

Registration

7002673

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

30

Latest update

08/06/2023

Trademark type

Word

Nice classes

5

Filing date

11/05/2021

Registration date

03/21/2023

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

03/21/2023

Last transaction

03/21/2023

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

25

Owner location

CH

Examiner

WU, KRISTEN ZAHNOW

Law office

M50

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Novartis AG

Representatives

Maury M. Tepper, III Tepper & Eyster, PLLC

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Publications

History of USPTO decisions and trademark events.

30 publications found

FINV

FINAL DECISION TRANSACTION PROCESSED BY IB

08/06/2023

FICS

FINAL DISPOSITION NOTICE SENT TO IB

07/11/2023

FIMP

FINAL DISPOSITION PROCESSED

07/11/2023

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

06/21/2023

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

03/21/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

03/21/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

01/03/2023

PUBO

PUBLISHED FOR OPPOSITION

01/03/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

12/14/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

11/29/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

11/01/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

11/01/2022

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

11/01/2022

RFNT

REFUSAL PROCESSED BY IB

06/12/2022

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

05/02/2022

RFRR

REFUSAL PROCESSED BY MPU

05/02/2022

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

03/19/2022

CNRT

NON-FINAL ACTION WRITTEN

03/18/2022

DOCK

ASSIGNED TO EXAMINER

03/16/2022

RNWL

INTERNATIONAL REGISTRATION RENEWED

02/17/2022

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

01/26/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

01/26/2022

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

01/26/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

01/26/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

01/26/2022

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

01/26/2022

MAFR

APPLICATION FILING RECEIPT MAILED

01/08/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

01/04/2022

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

01/03/2022

SDRC

SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB

12/23/2021

Continuous trademark protection

Get notified about every new filing that threatens ENAVISE or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.